Medtronic PLC vs Direxion Daily FTSE China Bull 3x Shares — how do they compare? Medtronic PLC trades at $89.87 (market cap $116.07B), while Direxion Daily FTSE China Bull 3x Shares trades at $28.84. The key difference: Medtronic PLC pays a 3.18% dividend while Direxion Daily FTSE China Bull 3x Shares pays none, and Medtronic PLC is trading nearer its 52-week high, Direxion Daily FTSE China Bull 3x Shares nearer its low. Which is the better fit depends on your goals.
| MDT | YINN | |
|---|---|---|
Market Cap | $116.07B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $105.35 | $56.62 |
52-Week Low | $73.75 | $21.45 |
Enterprise Value | $134.82B | — |
Dividend Yield | 3.18% | — |
Signals from Pluang's Aura AI — not financial advice
Medtronic (MDT) trades at $89.41, up 2.58% on the day, reflecting positive momentum. The stock exhibits bullish technical signals with strong moving average support and a consensus analyst price target of $98.75. Fundamentally, the company reported revenue of $33.54B for 2025 with a net income margin of 13.2%, and has consistently beaten EPS estimates in recent quarters. Recent news highlights institutional acquisitions and positive developments in medical technology platforms.
The outlook for MDT is positive, driven by earnings beats, robust cash flow, and growth in cardiac and robotic surgery segments. Key opportunities include undervaluation relative to analyst targets and dividend stability. Risks involve rising debt levels and competitive pressures in the medtech sector. The stock presents a compelling case for growth-oriented income investors.
YINN, a leveraged ETF tracking Chinese equities, trades at $29.20, down 9.6% in 24 hours amid bearish technical signals. Key support lies at $29, with resistance at $30–31. The fund's structure amplifies volatility, and financial ratios are unavailable due to its ETF nature. Recent news highlights China's AI investments and trade resilience, but geopolitical tensions and regulatory scrutiny persist.
Outlook remains cautious due to leverage risks and China's economic uncertainties. Opportunities exist if Hang Seng rebounds, but investors face elevated volatility from US-China frictions and ETF decay. Risks outweigh near-term catalysts, warranting careful position sizing.
Trailing returns across standard periods
Latest headlines on both assets
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →YINN is a leveraged ETF that seeks daily investment results, before fees and expenses, of 300% (3x) of the daily performance of the FTSE China 50 Index. It is a tactical instrument designed for sophisticated traders seeking to magnify short-term bullish views on large-cap Chinese equities, primarily those trading on the Hong Kong Stock Exchange.
Read more on YINN →